Amphastar Pharmaceuticals, Inc. Proceeds from Long-Term Debt Issued
Amphastar Pharmaceuticals, Inc. (AMPH) reported Proceeds from Long-Term Debt Issued of $845.00 million for the 12-month period ending 2023-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2026-02-26
- Amphastar Pharmaceuticals, Inc. proceeds from issuance of long-term debt for the quarter ending 2023-12-31 was $0.00.
- Amphastar Pharmaceuticals, Inc. proceeds from issuance of long-term debt for the quarter ending 2023-09-30 was $345.00M.
- Amphastar Pharmaceuticals, Inc. proceeds from issuance of long-term debt for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. proceeds from issuance of long-term debt for the quarter ending 2020-12-31 was $3.22M.
- Amphastar Pharmaceuticals, Inc. proceeds from issuance of long-term debt for fiscal 2023 was $845.00M.
- Amphastar Pharmaceuticals, Inc. proceeds from issuance of long-term debt for fiscal 2021 was $70.00M, a 1014.12% increase from fiscal 2020.
- Amphastar Pharmaceuticals, Inc. proceeds from issuance of long-term debt for fiscal 2020 was $6.28M, a 75.99% increase from fiscal 2019.
- Amphastar Pharmaceuticals, Inc. proceeds from issuance of long-term debt for fiscal 2019 was $3.57M, a 57.66% decline from fiscal 2018.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $345.00M derived: sum of 2 quarters · filed 2026-02-26 | $845.00M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $345.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $845.00M 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $500.00M 10-Q · filed 2024-08-09 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $70.00M 10-K · filed 2024-02-29 | ||
| 2021-09-30 | $70.00M 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $3.22M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $3.22M derived: sum of 2 quarters · filed 2023-03-01 | $3.22M derived: sum of 3 quarters · filed 2023-03-01 | $6.28M 10-K · filed 2023-03-01 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 derived: sum of 2 quarters · filed 2021-11-09 | $3.07M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $3.07M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $3.07M 10-Q · filed 2021-05-07 | |||
| 2019-12-31 | $3.57M 10-K · filed 2022-03-11 | |||
| 2018-12-31 | $431.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $431.00K derived: sum of 2 quarters · filed 2021-03-15 | $8.43M 10-K · filed 2021-03-15 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $8.00M 10-Q · filed 2019-11-08 | ||
| 2018-06-30 | $8.00M 10-Q · filed 2019-08-09 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $7.87M derived: sum of 2 quarters · filed 2020-03-16 | $18.98M 10-K · filed 2020-03-16 | |
| 2017-09-30 | $7.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $18.98M 10-Q · filed 2018-11-09 | ||
| 2017-06-30 | $11.12M 10-Q · filed 2018-08-09 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $3.59M derived: sum of 2 quarters · filed 2019-03-15 | $6.47M derived: sum of 3 quarters · filed 2019-03-15 | $10.20M 10-K · filed 2019-03-15 |
| 2016-09-30 | $3.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $6.47M derived: sum of 2 quarters · filed 2017-11-09 | $10.20M 10-Q · filed 2017-11-09 | $10.20M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-06-30 | $2.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $6.61M 10-Q · filed 2017-08-09 | $6.61M derived: sum of 3 quarters · filed 2018-03-14 | $6.61M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-03-31 | $3.73M 10-Q · filed 2017-05-10 | $3.72M derived: sum of 2 quarters · filed 2018-03-14 | $3.72M derived: sum of 3 quarters · filed 2018-03-14 | $3.72M derived: sum of 4 quarters · filed 2018-03-14 |
| 2015-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | -$1.00K derived: sum of 2 quarters · filed 2018-03-14 | -$4.00K derived: sum of 3 quarters · filed 2018-03-14 | $6.79M 10-K · filed 2018-03-14 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$3.00K derived: sum of 2 quarters · filed 2016-11-09 | $6.79M 10-Q · filed 2016-11-09 | $6.79M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-06-30 | -$3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $6.79M 10-Q · filed 2016-08-09 | $6.79M derived: sum of 3 quarters · filed 2017-03-15 | $6.79M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-03-31 | $6.79M 10-Q · filed 2016-05-10 | $6.79M derived: sum of 2 quarters · filed 2017-03-15 | $6.79M derived: sum of 3 quarters · filed 2017-03-15 | |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $0.00 derived: sum of 2 quarters · filed 2017-03-15 | $26.50M 10-K · filed 2017-03-15 | |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $26.50M 10-Q · filed 2015-11-13 | ||
| 2014-06-30 | $26.50M 10-Q · filed 2015-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |